Check the article out below ... it's pretty revolutionary but scary.

FDA panel to consider approval of race-specific heart failure drug

An FDA panel this Thursday will consider whether NitroMed’s BiDil, a drug found to significantly improve survival among African-American patients with moderate to advanced heart failure, should become the first drug intended for use by a specific racial group, the New York Times reports. After being rejected for general approval in 1997 because of “inconclusive evidence” in clinical trials, BiDil in 2004 was called one of the year’s “top developments” by the American Heart Association after a study of 1,050 African-American heart failure patients found that the drug “significantly reduced death and hospitalization” by widening participants’ blood vessels. Industry analysts say that if BiDil is approved, NitroMed will be able to use the drug’s “racially specific indication” to extend patent protection by an additional 13 years; they add that the drug’s annual sales have the potential to reach $825 million. However, although NitroMed maintains that its decision to test the drug solely in African Americans is based on “solid science,” some medical ethicists and scientists worry that “race is too broad and ill-defined a category to be relevant in determining a drug’s approval.” For instance, a researcher who last year reviewed BiDil in the Yale Journal of Health Policy, Law, and Ethics said that the drug’s approval as an African-American-only drug “would give an official ring to the discredited idea that race is a biological category.” In addition, many physicians contend that BiDil may also work in patients of other ethnicities and say that tests are needed to determine whether the drug is more effective in African-American patients. The Times notes that if the FDA panel recommends approval of BiDil, it would “go well beyond where it has in the past in using race as a category to evaluate which patients respond to drugs” (Saul, Times, 6/13; Daily Briefing, 11/9/04). For more information about the results of the trial investigating BiDil in African-American heart failure patients and the debate about ethnically targeted therapies, please see the Nov., 18, 2004 Cardiovascular Watch.
*****

So I'm like thinking if they have the technology to make racial specific therapy drugs, doesn't this also mean they have the technology to make racial specific biological weapons or disease as well?

The conspiracy theorist in me is coming out!